Alveolar rhabdomyosarcoma is a rare and aggressive form of soft tissue cancer that develops in skeletal muscle cells, primarily affecting adolescents and young adults. This challenging disease requires prompt diagnosis and intensive treatment combining surgery, chemotherapy, and radiation therapy.

Epidemiology

Alveolar rhabdomyosarcoma, commonly known as ARMS, represents a rare type of cancer within the broader category of soft tissue sarcomas (cancers that develop in connective tissues like muscles, tendons, and fat). Each year, approximately 400 to 500 people in the United States receive a diagnosis of all types of rhabdomyosarcoma combined, with ARMS accounting for roughly 20 to 30 percent of these cases.^[1][4] This means ARMS affects about one person per million children and adolescents annually, making it an exceptionally uncommon disease even within the category of childhood cancers.^[4]

In England, statistics show an average of 31 cases of alveolar rhabdomyosarcoma diagnosed each year, representing just over a quarter of all rhabdomyosarcoma diagnoses in that country.^[5] Overall, rhabdomyosarcoma accounts for roughly 3 percent of all childhood malignancies, with ARMS making up approximately 1 percent of cancers found in children and adolescents.^[4] Despite these low numbers, rhabdomyosarcoma remains the most common type of soft tissue cancer in children, with around 350 new cases diagnosed annually throughout the United States.^[3][11]

The age distribution of alveolar rhabdomyosarcoma differs notably from other types of rhabdomyosarcoma. ARMS most commonly affects older children, teenagers, and young adults, with a peak incidence among individuals between the ages of 10 and 25 years.^[5][7] Some cases have also been observed in adults over 40 years of age, though this is less common.^[7] This age pattern stands in contrast to embryonal rhabdomyosarcoma, the most common type of rhabdomyosarcoma, which typically affects younger children under age 10.^[3]

Unlike some cancers that show a clear gender preference, alveolar rhabdomyosarcoma occurs roughly equally in males and females, with no significant difference in incidence between the sexes.^[5][7] Additionally, there is no particular racial or ethnic group that demonstrates an unusually high rate of this disease, meaning ARMS can affect children and young adults from all backgrounds.^[1]

Causes

The precise cause of alveolar rhabdomyosarcoma remains largely unknown to medical science. However, researchers have identified that the disease develops when immature muscle cells undergo genetic mutations, transforming into cancerous cells that multiply uncontrollably and form tumors.^[1] These cancer cells should have developed into normal skeletal muscle cells—the muscles that attach to bones and help control voluntary body movements—but instead began growing abnormally.^[8]

Unlike many other cancers, there is no genetic predisposition for developing ARMS in most cases. The disease typically occurs sporadically, meaning it appears randomly without running in families.^[4] However, specific genetic changes do occur within the cancer cells themselves. Approximately 60 percent of all ARMS cases test positive for a fusion gene called PAX3-FOXO1, while another 20 percent are positive for PAX7-FOXO1 fusion gene. The remaining 20 percent of cases are fusion-negative, meaning they do not contain these characteristic genetic abnormalities.^[4]

These fusion genes form through specific chromosomal rearrangements. For PAX3-FOXO1 to develop, part of chromosome 13 must translocate (move) to chromosome 2. For PAX7-FOXO1, part of chromosome 13 translocates to chromosome 1.^[4] Both fusion genes combine DNA-binding domains from PAX proteins with transactivation domains from FOXO1, creating abnormal proteins that disrupt normal cell function and act as oncogenes—genes that promote cancer formation.^[4] Research has shown that PAX3-FOXO1 drives cancer-promoting gene expression programs through the creation of distant genetic elements called super enhancers.^[4]

Risk Factors

While most cases of alveolar rhabdomyosarcoma occur without any identifiable risk factors, certain rare inherited genetic conditions increase a child’s likelihood of developing this cancer. It’s important to understand that even with these conditions, the overall risk remains quite low.^[1][8]

Children with Li-Fraumeni syndrome, a hereditary disorder that increases susceptibility to various cancers, face elevated risk for developing rhabdomyosarcoma.^[1][8] Similarly, Beckwith-Wiedemann syndrome, a condition characterized by overgrowth and increased cancer risk, also raises the likelihood of this disease.^[1][8] Neurofibromatosis type 1, which causes tumors to form on nerve tissue, represents another risk factor for rhabdomyosarcoma development.^[1][8]

Additional inherited conditions associated with increased risk include Costello syndrome, Cardiofasciocutaneous syndrome, Dicer1 syndrome, and Noonan syndrome.^[1][8] Each of these rare genetic disorders affects different body systems but shares the common feature of increasing cancer susceptibility to varying degrees.

Some research suggests that children who had a high birth weight or were larger than expected at birth may have an increased risk of developing embryonal rhabdomyosarcoma, though this association appears less clear for alveolar rhabdomyosarcoma specifically.^[8] In the overwhelming majority of cases, doctors cannot identify a specific cause or risk factor that explains why a particular child developed ARMS.^[8]

Symptoms

The symptoms of alveolar rhabdomyosarcoma vary significantly depending on where the tumor develops in the body and how large it has grown. Because ARMS is a highly aggressive cancer that grows rapidly, symptoms often prompt medical attention relatively quickly, though they may initially be mistaken for less serious conditions like injuries or infections.^[7]

The most common and characteristic symptom of ARMS is a lump, lesion, or swelling in the soft tissue under the skin. This growth most frequently appears in the arms, legs, or torso (the trunk of the body).^[1][3] The lump typically grows fast, becoming noticeably larger over time, and while it may be painful in some cases, it is often painless, which can delay recognition of its seriousness.^[5][11] Because alveolar rhabdomyosarcoma commonly develops in the extremities (arms and legs), patients or parents often first notice an unusual mass or swelling in these areas that doesn’t resolve on its own.^[1]

When tumors develop in the head and neck region, they can produce a distinct set of symptoms. A growth behind the eye may cause the eye to bulge outward or protrude from its socket. Patients may experience crossed eyes, vision problems, or loss of hearing and balance.^[5][8] Tumors in the nasal cavity or sinuses can lead to nosebleeds, sinus congestion, or chronic sinus infection symptoms.^[1] Some children develop weakness, numbness, or pain in their face, or may have trouble swallowing if the tumor affects nearby nerves or structures.^[5]

Alveolar rhabdomyosarcoma can also arise in the muscles around the spine (called the paraspinal region), leading to back pain, difficulty walking, or loss of bowel or bladder control due to nerve compression.^[5][7] When tumors develop in the area between the genitals and anus (the perineal region), patients may experience constipation, abdominal pain, swelling, bloating, or blood in the urine or stool.^[5][7]

In cases where ARMS has grown quite large or spread to other parts of the body (metastasized), additional symptoms can emerge. These include persistent bone pain, constant cough, general weakness, and unexplained weight loss.^[1] At diagnosis, approximately 25 to 30 percent of patients already have distant or locoregional metastases (cancer that has spread beyond the original tumor site) through lymphatic or hematogenous spread (through the lymph system or bloodstream).^[7]

Some specific symptoms relate to tumor location in less common sites. For tumors in the urinary or reproductive organs, children may notice difficulty urinating, pain when urinating, or blood in the urine.^[3][11] Rarely, ARMS can present as primary disseminated tumors resembling leukemia, though this presentation is uncommon.^[7]

Prevention

Unfortunately, there are no known methods to prevent alveolar rhabdomyosarcoma. Because the disease typically occurs sporadically without identifiable environmental causes or modifiable risk factors, standard cancer prevention strategies such as lifestyle changes, dietary modifications, or avoiding specific exposures do not apply to ARMS.^[1]

For families with known inherited genetic conditions that increase cancer risk, genetic counseling can provide valuable information about surveillance strategies and early detection approaches. Children with syndromes like Li-Fraumeni, Beckwith-Wiedemann, or neurofibromatosis may benefit from regular medical monitoring and prompt evaluation of any unusual symptoms, though this represents early detection rather than true prevention.^[1][8]

The most important preventive measure available is awareness. Parents, caregivers, and healthcare providers should be alert to persistent lumps, swellings, or other concerning symptoms in children and adolescents. While most lumps and bumps in young people are harmless, any growth that doesn’t go away, continues to enlarge, or is accompanied by other worrisome symptoms deserves medical evaluation.^[1] Recognizing symptoms early can lead to faster diagnosis and treatment, potentially improving outcomes even though it doesn’t prevent the disease from occurring initially.^[3]

Regular well-child visits with a pediatrician provide opportunities for health monitoring and symptom discussion. Maintaining a relationship with healthcare providers ensures that concerning changes receive appropriate attention and investigation when they arise.

Pathophysiology

Alveolar rhabdomyosarcoma develops from cells that should have matured into skeletal muscle tissue. During normal development, muscle precursor cells in the mesoderm (the middle layer of embryonic tissue) follow a carefully controlled pathway to become functional skeletal muscle.^[4] In ARMS, this process goes awry, and immature cells instead transform into cancer cells that multiply uncontrollably.

Under a microscope, ARMS cells appear small with minimal cytoplasm (the gel-like substance inside cells). The cell nuclei are round and contain normal-appearing chromatin structures (the material that makes up chromosomes).^[4] A characteristic feature is that ARMS cells often clump together with fibrovascular septa—thin walls containing blood vessels and fibrous tissue—interrupting the aggregates. These fibrovascular septa create a pattern that resembles the alveoli (tiny air sacs) found in the lungs, which is why this cancer is called “alveolar” rhabdomyosarcoma.^[4] In some cases, tumors may lack these septa and have a more solid appearance without the alveolar pattern.^[4]

The molecular changes in ARMS cells involve the fusion proteins PAX3-FOXO1 or PAX7-FOXO1 mentioned earlier. PAX3 and PAX7 are transcription factors—proteins that control which genes are turned on or off—and play essential roles in normal muscle development (myogenesis). When fused with FOXO1, these proteins become abnormal oncoproteins that affect multiple cellular pathways controlling growth, survival, differentiation, and other functions.^[7] They activate numerous downstream target genes including MET, ALK, FGFR4, MYCN, IGF1R, and MYOD1, driving the cancerous behavior of cells.^[7]

Approximately 70 percent of PAX7-FOXO1 fusion-positive tumors show amplification (extra copies) of the fusion gene, while only about 5 percent of PAX3-FOXO1 fusion-positive tumors are amplified.^[4] This genetic amplification can influence how aggressive the cancer behaves. Additional genetic changes may occur in some cases, including amplification of regions containing the MYCN oncogene and CDK4, particularly in PAX3-FOXO1 positive tumors.^[7]

ARMS is characterized by its aggressive biological behavior. The cancer grows rapidly and has a strong tendency to spread (metastasize) to other parts of the body early in its course.^[1][3] Common metastatic sites include the lungs, bone marrow, and lymph nodes.^[4] The cancer can spread through both the lymphatic system and through the bloodstream (hematogenous spread), allowing cancer cells to establish new tumors in distant locations.^[7] This aggressive nature and tendency for early spread distinguish alveolar rhabdomyosarcoma from embryonal rhabdomyosarcoma and contribute to its poorer prognosis.^[1]

Specialized laboratory techniques can distinguish ARMS from other types of rhabdomyosarcoma. Immunostaining for proteins called myogenin and MyoD helps confirm that cells have skeletal muscle characteristics, while staining for AP2β and p-cadherin can distinguish fusion-positive ARMS from fusion-negative cases.^[4] These molecular and pathological features guide treatment decisions and provide prognostic information about how the cancer is likely to behave.